Loading
Iterum Therapeutics plc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Dunne Michael W., was filed 20 Nov 2025.
Iterum Therapeutics plc: what insiders have been doing
This page follows insider dealings at Iterum Therapeutics plc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. From 19 October 2025 to 19 October 2026, the disclosure feed for Iterum Therapeutics plc logged 1 filing by 1 insider.
No insider sold shares on the market over the period. Instead, the filings list 1 purchase totalling €1,891, made by 1 insider. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. One trade stands out by size: a purchase of €1,891 from Dunne Michael W., disclosed on 20 November 2025. Among those who bought: 1 senior executive.
The most recent open-market purchase was published on 20 November 2025, 335 days ago.
Compared with its exchange (5,458 companies, median 22 filings), a count of 1 filing is below the norm. Looking back to 2021, when coverage begins, insiders filed 7 purchases and 6 sales.
In the same sector, recent insider purchases at Vivos Inc and Anixa Biosciences Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
41
Thresholds
n/a
Buy Volume
€133,934
7 ops. · all time
Sell Volume
€125,516
6 ops. · all time
Who traded when
BuySaleMichael W. Dunne2 buys
Since the insiders bought
- -42.8%Entry US$0.39 · Close at T+90 US$0.22
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
US$0.03
Analyst consensus
Income statement
Gross profit-US$254k
EBITDA-US$21.7M
Net income-US$24.8M0.0% margin
Valuation
Beta3.82
Balance sheet & cash
Market capUS$532
Total debtUS$45.5M
Free Cash Flow-US$26.8M
Profitability & ownership
ROA-53.3%
% insiders0.8%
% institutions0.5%
Last declaration on 20 November 2025
Declarations41 total
6,000 shares@ US$0.36521.6% of flowOrdinary SharesSEC:0001193125-25-288848:0
Canonical exit: 16 Feb 2026 (T+90)
15,000 shares@ US$0.72367.8% of flowOrdinary SharesSEC:0000950170-25-106908:0
Canonical exit: 6 Nov 2025 (T+90)
182,453 sharesOrdinary SharesSEC:0000950170-24-095094:0
106,247 sharesOrdinary SharesSEC:0000950170-24-095096:0
82,613 sharesOrdinary SharesSEC:0000950170-24-095095:0
25,000 shares@ US$1.4026.6% of flowOrdinary SharesSEC:0001209191-23-059750:0
Canonical exit: 21 Mar 2024 (T+90)
10,000 shares@ US$1.844214.2% of flowOrdinary SharesSEC:0001209191-23-059133:0
Canonical exit: 17 Mar 2024 (T+90)
8,333 shares0Ordinary SharesSEC:0001209191-23-057258:0
20,000 shares@ US$2.034531.2% of flowOrdinary SharesSEC:0001209191-23-056685:0
Canonical exit: 20 Feb 2024 (T+90)
10,000 shares@ US$1.5863100.0% of flowOrdinary SharesSEC:0001209191-23-056092:0
Canonical exit: 18 Feb 2024 (T+90)
5,479 sharesOrdinary SharesSEC:0001209191-23-050912:0
3,487 sharesOrdinary SharesSEC:0001209191-23-050911:0
1,779 sharesOrdinary SharesSEC:0001209191-23-040406:0
2,796 sharesOrdinary SharesSEC:0001209191-23-040405:0
15,853 shares0Ordinary SharesSEC:0001209191-23-037406:0
15,853 shares0Ordinary SharesSEC:0001209191-23-037407:0
1,299 shares0Ordinary SharesSEC:0001209191-23-034106:0
1,299 shares0Ordinary SharesSEC:0001209191-23-022422:0
2,041 shares0Ordinary SharesSEC:0001209191-23-022424:0
6,666 shares0Ordinary SharesSEC:0001209191-23-018585:0
14,333 shares0Ordinary SharesSEC:0001209191-23-018584:0
761 sharesOrdinary SharesSEC:0001209191-23-001287:0
1,197 sharesOrdinary SharesSEC:0001209191-23-001286:0
8,334 shares0Ordinary SharesSEC:0001209191-22-059733:0
25 of 41 declarations
About Iterum Therapeutics plc
Iterum Therapeutics plc is a biopharmaceutical company focused on anti-infectives and is listed on the Nasdaq in the United States under the ticker ITRM. For French-speaking investors, it fits the profile of a specialty pharma name with high regulatory sensitivity: the equity story depends on clinical execution, FDA decisions, commercialization milestones, and access to reimbursement rather than on a broad, diversified product portfolio. The company was incorporated in June 2015 under Irish law and later re-registered as a public limited company in March 2018. Its operating footprint is tied to Dublin and Chicago, but its public market listing and commercial opportunity are centered in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm?utm_source=openai))
Iterum’s business is built around developing and commercializing anti-infectives designed to address infections caused by multidrug-resistant pathogens in both community and hospital settings. Its lead asset and only marketed product is ORLYNVAH™ (sulopenem etzadroxil and probenecid), an oral penem antibiotic. In October 2024, the FDA approved ORLYNVAH™ for the treatment of uncomplicated urinary tract infections in adult women who have limited or no alternative oral antibacterial treatment options, and the company launched the product commercially in the U.S. in August 2025. Iterum describes ORLYNVAH™ as the first and only approved oral penem antibiotic in the United States, which gives the company a differentiated niche position despite its small scale. ([ir.iterumtx.com](https://ir.iterumtx.com/press-releases/detail/136/iterum-therapeutics-receives-u-s-fda-approval-of?utm_source=openai))
Read moreShow less
From a competitive standpoint, Iterum is still a small-cap biotech/pharma commercial launch story and remains highly dependent on a single product. Its strategic value comes from the medical need in resistant infections, the limited availability of effective oral options in the uUTI setting, and the regulatory barrier created by FDA approval. The company also highlighted the publication of its REASSURE phase 3 trial in NEJM Evidence, supporting the clinical credibility of oral sulopenem. In 2025, management stated that product revenues were still modest in the early launch phase and that cash resources were intended to fund operations into 2026. ([ir.iterumtx.com](https://ir.iterumtx.com/press-releases/detail/150/iterum-therapeutics-announces-publication-of-reassure-trial?utm_source=openai))
For investors, the key variables are uptake of ORLYNVAH™, prescription growth, payer coverage, sales-force effectiveness, and the company’s ability to extend its cash runway. This is therefore best viewed as a commercialization-stage specialty pharma company rather than a mature diversified antibiotic platform. A major risk factor emerged in March 2026, when the company disclosed that the High Court in Ireland appointed joint liquidators to Iterum Therapeutics plc and Iterum Therapeutics International Limited, a development that materially changes the risk profile and must be factored into any investment view. ([iterumtx.com](https://www.iterumtx.com/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
